Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F☒ Form 40-F☐
CONTENTS
Evogene Ltd. (the "Registrant" or the "Company") hereby announces that, excluding the resolution with respect to grant of options to our CEO, which was rejected, the shareholders of the Company approved all the proposals brought before the annual general meeting of shareholders held on June 13, 2024 (following a one-week adjournment from the original meeting date) (the "Meeting"), by the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company's articles of association, as described in the Proxy Statement which was attached as Exhibit 99.2 to the Company's Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission ("SEC"), on April 30, 2024, and sent in connection with the Meeting.
The contents of this Report of Foreign Private Issuer on Form 6-K (this "Form 6-K") is incorporated by reference in the registration statements on Form F-3 (SEC File No. 333-277565), and Form S-8 (SEC File Nos. 333-193788,333-201443,333-203856 and 333-259215) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
EVOGENE LTD.
(Registrant)
Date: June 17, 2024
By: /s/ Yaron Eldad
--------------
Yaron Eldad
Chief Financial Officer
Attachments
Original Link
Original Document
Permalink
Disclaimer
Evogene Ltd. published this content on
17 June 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
17 June 2024 20:06:17 UTC.
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
EVOGENE LTD. 
